西罗莫司治疗静脉畸形研究现状

doi:10.19438/j.cjoms.2020.06.001

中国口腔颌面外科杂志 ›› 2020, Vol. 18 ›› Issue (6): 553-558.doi: 10.19438/j.cjoms.2020.06.001

西罗莫司治疗静脉畸形研究现状

郑家伟

上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海市口腔医学研究所,上海 200011

收稿日期:2020-10-20 修回日期:2020-10-30 发布日期:2020-12-31
通讯作者: 郑家伟,E-mail:davidzhnegjw@hotmail.com
作者简介:郑家伟(1964-),男,博士,教授,博士研究生导师
基金资助:
国家自然科学基金(81771087,82071130)

Advances of using sirolimus to treat venous malformations

ZHENG Jia-wei

Department of Oromaxillofacial Head and Neck Oncology,Shanghai Ninth People's Hospital,College of Stomatology,Shanghai Jiao Tong University School of Medicine; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology. Shanghai 200011, China

Received:2020-10-20 Revised:2020-10-30 Published:2020-12-31

摘要/Abstract

摘要： 静脉畸形是临床上最常见的血管畸形,大多数是由于编码TIE2或PI3K基因中的功能获得性体细胞突变引起的。复杂或顽固性静脉畸形的治疗,仍然是临床上面临的难题和挑战。西罗莫司为mTOR抑制剂,是第一个用于静脉畸形的靶向药物,其疗效和安全性近年来颇受关注。本文就西罗莫司用于治疗静脉畸形的相关问题进行综述。

关键词: 静脉畸形, 西罗莫司, 雷帕霉素, mTOR抑制剂, 靶向分子治疗

Abstract: Venous malformations are the most common vascular malformations seen in the clinic, most of them are caused by gain-of-function somatic mutations in the genes encoding TIE2 or PI3K. Management of complicated or refractory lesions is still a great challenge for clinicians. mTOR inhibitor sirolimus is the first targeting agent for venous malformation treatment, its efficacy and safety have attracted much attention in recent years. This article reviewed the related problems and advances of using sirolimus to treat venous malformationsl.

Key words: Venous malformations, Sirolimus, Rapamycin, mTOR inhibitor, Targeted molecular therapy

中图分类号:

R739.8

郑家伟. 西罗莫司治疗静脉畸形研究现状[J]. 中国口腔颌面外科杂志, 2020, 18(6): 553-558.

ZHENG Jia-wei. Advances of using sirolimus to treat venous malformations[J]. China J Oral Maxillofac Surg, 2020, 18(6): 553-558.

参考文献

[1] Uebelhoer M, Boon LM, Vikkula M.Vascular anomalies: from genetics toward models for therapeutic trials[J]. Cold Spring Harb Perspect Med, 2012, 2(8): a009688.
[2] Soblet J, Kangas J, Nätynki M, et al.Blue Rubber Bleb Nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations[J]. J Invest Dermatol, 2017, 137(1): 207-216.
[3] 国际血管联盟中国分部血管畸形专家委员会.静脉畸形中国专家共识[J].介入放射学杂志,2019,28(3):307-311.
[4] Dompmartin A, Acher A, Thibon P, et al.Association of localized intravascular coagulopathy with venous malformations[J]. Arch Dermatol, 2008, 144(7): 873-877.
[5] Boon LM, Vanwijck R.Medical and surgical treatment of venous malformations[J]. Ann Chir Plast Esthet, 2006, 51(4-5): 403-411.
[6] Boutouja F, Stiehm CM, Platta HW. mTOR: a cellular regulator interface in health and disease[J]. Cells, 2019, 8(1): 18-41.
[7] Hu HT, Huang YH, Chang YA, et al.Tie2-R849W mutant in venous malformations chronically activates a functional STAT1 to modulate gene expression[J]. J Invest Dermatol, 2008, 128(9): 2325-2333.
[8] Soblet J, Limaye N, Uebelhoer M, et al.Variable somatic TIE2 mutations in half of sporadic venous malformations[J]. Mol Syndromol, 2013, 4(4): 179-183.
[9] Wouters V, Limaye N, Uebelhoer M, et al.Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects[J]. Eur J Hum Genet, 2010, 18(4): 414-420.
[10] Limaye N, Kangas J, Mendola A, et al.Somatic activating PIK3CA mutations cause venous malformation[J]. Am J Hum Genet, 2015, 97(6): 914-921.
[11] Castillo SD, Tzouanacou E, Zaw-Thin M, et al. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans [J]. Sci Transl Med, 2016, 8(332): 332ra43.
[12] Uebelhoer M, Nätynki M, Kangas J, et al.Venous malformation causative TIE2 mutations mediate an AKT dependent decrease in PDGF-b[J]. Hum Mol Genet, 2013, 22(17): 3438-3448.
[13] Nätynki M, Kangas J, Miinalainen I, et al.Common and specific effects of TIE2 mutations causing venous malformations[J]. Hum Mol Genet, 2015, 24(22): 6374-6389.
[14] Boscolo E, Limaye N, Huang L, et al.Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects[J]. J Clin Invest, 2015, 125(9): 3491-3504.
[15] di Blasio L, Puliafito A, Gagliardi PA, et al. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations[J]. Cell Death Dis, 2018, 9(2): 45-60.
[16] Castel P, Carmona FJ, Grego-Bessa J, et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations[J]. Sci Transl Med, 2016, 8(332):332ra42.
[17] Hammer J, Seront E, Duez S, et al.Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase Ⅱ study[J]. Orphanet J Rare Dis, 2018, 13(1): 191-204.
[18] Seront E, Van Damme A, Boon LM, et al.Rapamycin and treatment of venous malformations[J]. Curr Opin Hematol, 2019, 26(3): 185-192.
[19] Janssens P, Dekeuleneer V, Van Damme A, et al.Angiosarcoma arising from congenital primary lymphedema[J]. Pediatr Dermatol, 2018, 35(6): e382-e388.
[20] Adams DM, Trenor CC, Hammill AM, et al.Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies[J]. Pediatrics, 2016, 137(2): e20153257.
[21] Fruman DA, Chiu H, Hopkins BD, et al.The PI3K pathway in human disease[J]. Cell, 2017, 170(4): 605-635.
[22] Venot Q, Blanc T, Rabia SH, et al.Targeted therapy in patients with PIK3CA-related overgrowth syndrome[J]. Nature, 2018, 558(7711): 540-546.

西罗莫司治疗静脉畸形研究现状

Advances of using sirolimus to treat venous malformations

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邰茂众, 秦中平, 郑家伟, 李克雷, 刘学键, 李凯, 袁斯明, 范新东, 周德凯, 董长宪, 吉毅, 顾松, 霍然, 杨耀武, 王绪凯. 局限性血管内凝血诊断与治疗中国专家共识[J]. 中国口腔颌面外科杂志, 2024, 22(4): 313-321.
[2]	张芳, 寿卫东, 李妍. 医护协同下聚多卡醇泡沫硬化剂治疗头颈部静脉畸形疗效评价[J]. 中国口腔颌面外科杂志, 2024, 22(3): 274-278.
[3]	李晓, 王豪伟, 杨西涛, 王德明, 范新东, 苏立新. 颌骨骨内动静脉畸形介入栓塞治疗远期疗效分析[J]. 中国口腔颌面外科杂志, 2024, 22(1): 78-83.
[4]	闫婷婷, 张鹏, 韩合理, 王荷静, 王奇民, 陈行, 袁荣涛. 腭静脉畸形合并遗传性出血性毛细血管扩张症1例报告[J]. 中国口腔颌面外科杂志, 2023, 21(6): 626-629.
[5]	闫志伟, 沈艳玲, 郭军, 刘源, 杨霞, 李欢, 冯瑶, 孙沫逸, 杨耀武. 纤维蛋白胶复合平阳霉素栓塞硬化治疗面颈部静脉畸形的实验研究[J]. 中国口腔颌面外科杂志, 2023, 21(4): 340-344.
[6]	李晓, 范新东, 郑家伟. 脉管异常的ISSVA分类概要及分子生物学研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(3): 286-290.
[7]	庄乾伟, 李芳芳, 孟箭, 顾倩平, 李志萍. 射频消融联合经皮造影DSA引导下聚多卡醇泡沫硬化剂灌注治疗口腔颌面部静脉畸形38例疗效评价[J]. 中国口腔颌面外科杂志, 2022, 20(2): 135-140.
[8]	吴海威, 于淼, 郑家伟. 口腔颌面部静脉畸形诊治：经验与进展[J]. 中国口腔颌面外科杂志, 2021, 19(2): 186-192.
[9]	靳能皓, 南欣荣, 闫星泉, 李明. 手术结合平阳霉素注射治疗巨舌症1例报告[J]. 中国口腔颌面外科杂志, 2020, 18(2): 190-192.
[10]	雷书赞, 汪接兵, 张银喜. 气管切开全麻下无水乙醇栓塞治疗咽喉部静脉畸形20例报道[J]. 中国口腔颌面外科杂志, 2019, 17(1): 74-76.
[11]	杜仲, 马海龙, 张凌, 郑家伟, 王延安. TIE2-R849W突变斑马鱼模型的建立及其在静脉畸形发病中的作用探讨[J]. 中国口腔颌面外科杂志, 2018, 16(1): 6-11.
[12]	闫志伟, 张春谊, 郭军, 杨霞, 王维戚, 杨涛, 孙沫逸, 杨耀武. 纤维蛋白胶复合平阳霉素栓塞硬化治疗面颈部动静脉畸形效果观察[J]. 中国口腔颌面外科杂志, 2018, 16(1): 52-55.
[13]	黄子贤, 陈耀庭, 李世豪, 范松, 张大明, 汪延, 严凌健, 陈伟良, 黄志权. 4例儿童期颌骨动静脉畸形血管复通的再治疗[J]. 中国口腔颌面外科杂志, 2017, 15(4): 329-333.
[14]	黄子贤，陈耀庭，李世豪，范松，张大明，汪延，严凌健，陈伟良，黄志权. 4例儿童期颌骨动静脉畸形血管复通的再治疗[J]. 中国口腔颌面外科杂志, 2017, 15(4): 368-372.
[15]	辜健敏, 孟箭, 顾倩平, 张杰, 李志萍, 王兴. 射频消融技术联合DSA引导下无水乙醇介入治疗口腔颌面部难治性动静脉畸形的疗效观察[J]. 中国口腔颌面外科杂志, 2017, 15(2): 157-160.